Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Feldman on Study of Active Surveillance in Younger Men With Prostate Cancer

September 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

September 6th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Dr. Badani on Determining Which Patients With RCC Will Receive Robotic Surgery

September 6th 2017

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Dr. Lallas on Understanding Immunotherapy in GU Malignancies

September 6th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Dr. Kaouk on Benefits of Robotic Partial Nephrectomy for RCC

September 1st 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Campbell Discusses Advancements in Kidney Cancer Management

August 29th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.

Dr. Nanus on Cytoreductive Nephrectomy for RCC

August 28th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses cytoreductive nephrectomy for patients with renal cell carcinoma (RCC).

Tivozanib Approved in Europe for Kidney Cancer

August 28th 2017

The European Commission has approved tivozanib for the treatment of patients with advanced renal cell carcinoma.

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

August 25th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Reduced-Dose Cabazitaxel Shows Efficacy in mCRPC

August 25th 2017

Results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer.

Lead Investigator Discusses Atezolizumab/Bevacizumab in mRCC

August 25th 2017

Michael B. Atkins, MD, discusses the latest IMmotion150 findings and additional developments with immunotherapy in mRCC.

Dr. Nanus Discusses Early Stage Kidney Cancer Treatment

August 25th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.

Dr. Campbell on the Future of the Management of RCC

August 24th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

Expert Discusses Impact of Muscle-Invasive Bladder Cancer Guidelines

August 24th 2017

The guidelines provide evidence-based recommendations on staging, neoadjuvant and adjuvant chemotherapy, radical cystectomy, urinary diversion, perioperative surgical management, and pelvic lymphadenectomy.

Update Offers New Insight on Atezolizumab/Bevacizumab Benefit in RCC

August 24th 2017

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Dr. Hammers on Next Steps with Immunotherapy in RCC

August 24th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer

August 23rd 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.

Dr. Feldman Discusses Metabolomic Findings in Prostate Cancer

August 23rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Expert Discusses Next Steps for Durvalumab in Bladder Cancer

August 23rd 2017

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.